TUC-S.R.L.
24.4.2024 09:36:30 CEST | Business Wire | Press release
TUC S.r.l., the Deep Tech Company known for TUC.technology, launches a fundamental evolution of its offer, TUC.tiny™. This mobility revolution comes with all the features at the base of the TUC.technology patent, issued in over 140 countries worldwide. A small jewel based on TUC's three technological pillars, mechanical structuring, electronic management and data exchange, designed to also interface with consumer electronics thanks to the integration of USB Type-C technology. TUC.tiny™ becomes the USB of Mobility, a solution that aims to reinvent the interaction between users and vehicles bringing together mobility and everyday life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424672317/en/
TUC dashboard (Photo: Business Wire)
A real blank canvas, which can be transformed and customized countless times thanks to TUC.tiny™ and TUC.technology™, flexibly adapting to every need and preference. With TUC's innovative patented technology, personal devices such as smartphones, tablets, speakers and voice automation systems can be securely integrated. At the same time, automotive-specific elements such as dashboards, switches for driving mode selection and climate control, navigation systems with integrated cameras, harmonize with accessories that can be used both in the car and at home, such as fragrance diffusers and ambient lights.
TUC S.r.l. is at the forefront of mobility innovation, specialized in the development of modular vehicle solutions that aims to simplify and revolutionize the concept of vehicles, from a defined product to a definable experience. Distinguishing itself for technological excellence at international level, TUC has achieved significant recognition. With the launch of TUC 3.0 in 2023, the company is setting new standards in the industry by partnering with leading global OEMs.
With TUC.tiny™ and its advanced interface – which includes physical fixing, electrical and data transfer connectivity – any device can be integrated into the modular design of the dashboard, making it immediately operational. This allows users to customize their mobile space with extreme ease and freedom. TUC.tiny™ is designed to support all everyday devices that have a USB Type-C connection. These can be integrated into TUC.tiny™ through a state-of-the-art module. The proposed solution stands out for its ability to blend harmoniously into any part of the vehicle, both inside and outside, ensuring direct and simple installation, both in the production phase and after-sales, eliminating the need to adopt inefficient and unsafe solutions such as suction cups or other impractical and unreliable systems. In addition, the robustness of TUC.tiny™ is ensured by a mechanical or electro-actuated locking system, which introduces the novelty of security offered by NFC technology for reliable control of locking and unlocking functions.
"We are proud of the results achieved thanks to our constant commitment over the last few years," comments Ludovico Campana, Inventor and CEO of TUC. “TUC.tiny™ represents our promise for the future; A vision of a world where technology and mobility come together in personalized experiences, designed around the needs of everyone. With TUC.technology®, we enable a paradigm shift, giving vehicle manufacturers tools to simplify development, engineering, and manufacturing, while enabling new business models that enhance continuous post-production customization. Our goal is that it is not the user who adapts to the life cycle of the vehicle, but that the vehicle can evolve to meet the changing needs of its user. We are thrilled with the results obtained by customers who are experimenting and adopting our technology, testifying to the validity and effectiveness of our work – continues Campana – This is the future that TUC S.r.l. is building: a mobility ecosystem where every innovation is guided by the values of democratization of technology, customization and sustainability, with the ambition to overcome current boundaries and explore new possibilities for a more connected and sustainable society. responsible."
The introduction of TUC.tiny™ is the completion of TUC.technology's offering. It marks a step towards the "democratization" of technology. The gateway to an advanced mobility experience becomes wider, easily accommodating the smart objects that animate our daily lives. This isn't just a technological advance; is TUC's invitation to imagine and build together the future of mobility, a world where technology unites us, improving every aspect of our daily journey.
ABOUT TUC.technology
TUC S.r.l. is a Deep-Tech company at the forefront of mobility innovation, specialized in the development of modular vehicle solutions that aim to simplify and revolutionize the concept of the vehicle, from a defined product to a definable experience. Distinguishing itself for technological excellence at an international level, TUC has achieved significant recognition, including exhibitions at CES in Las Vegas at the National Automobile Museum and recognition from major newspapers.
With the launch of TUC 3.0, the company is setting new standards in the industry by partnering with leading global OEMs. Learn more at www.tuc.technology.
Facebook @TUCtechnology
Instagram @tuc.technology
Twitter @TUCtechnology
Linkedin @TUC.technology
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424672317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
